Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma

NCT06730542 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

CNS Lymphoma

Interventions

DRUG: Zanubrutinib
DRUG: Methotrexate
DRUG: Polatuzumab Vedotin
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone

Sponsor

Juan P. Alderuccio, MD

Collaborators

BeiGene